Journey Colab is a groundbreaking brand that is revolutionizing addiction care through the use of psychedelic therapies. Their mission is to unlock the potential of psychedelics to provide lasting remission for patients struggling with addiction. Backed by top-tier investors, Journey Colab believes that the integration of psychedelic therapies, psychotherapy, and community support can create a powerful new model of addiction treatment.

Their approach involves enabling real-world research on psychedelic therapeutics and offering high-quality, integrated care through a network of Centers of Excellence. These centers, developed in collaboration with select addiction treatment centers across the U. S., advance the development of psychedelic therapies, including Journey's own drug program, JOUR-5700, which focuses on Mescaline HCl for Alcohol Use Disorder.

Journey Colab is dedicated to finding innovative solutions for addiction, a chronic and relapsing condition that affects over 20 million Americans. With only 10% of individuals receiving lasting benefit from current treatments, Journey Colab aims to make a difference. Their unique stakeholder structure ensures that the team is experienced and committed to creating scientifically rigorous and clinically validated treatments while promoting equitable access to care.

In fact, 10% of their founding equity is dedicated to sharing success with community stakeholders, including Indigenous communities, to improve access to care. If you're interested in getting involved or learning more about Journey Colab, you can contact them directly. Stay up to date with their latest news and research by signing up on their website